Genmab $GMAB
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS29
PHASE 3 / 2-317
RECRUITING10
READOUTS ≤12 MONTHS7
READOUT SLIPPED >6 MO64%
Delay Index: of 22 active trials registered more than a year ago, 14 have moved their primary completion (readout) date by more than 6 months since first registration (median +34.1 months). See all sponsors →
Open Genmab on the live radar map → 📅 $GMAB readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| EPCORE DLBCL-1 NCT04628494 |
P3 | Active, not recruiting | Diffuse Large B-cell Lymphoma | 483 | 2025-10-13 (+28 mo) |
| Epcoritamab NCT07226752 |
P3 | Active, not recruiting | Diffuse Large B-Cell Lymphoma | 72 | 2025-10-13 |
| GEN1042 NCT04083599 |
P1/2 | Active, not recruiting | Malignant Solid Tumor; Non-Small Cell Lung Cancer (NSCLC) | 350 | 2025-12-30 (+61 mo) |
| RAINFOL-02 NCT06619236 |
P3 | Active, not recruiting | Platinum-resistant Ovarian Cancer | 584 | 2026-08-18 (-5 mo) |
| Epcoritamab NCT05451810 |
P2 | Active, not recruiting | Diffuse Large B-Cell Lymphoma; Classic Follicular Lymphoma | 184 | 2027-03 (+19 mo) |
| EPCORE DLBCL-2 NCT05578976 |
P3 | Active, not recruiting | Diffuse Large B-Cell Lymphoma | 900 | 2027-06 (+34 mo) |
| Acasunlimab NCT06635824 |
P3 | Active, not recruiting | PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC | 191 | 2027-07-30 (+6 mo) |
| EPCORE™ NHL-3 NCT04542824 |
P1/2 | Active, not recruiting | Diffuse Large B Cell Lymphoma; High-grade B-cell Lymphoma | 78 | 2027-09 (+35 mo) |
| RAINFOL-02 NCT07604766 |
P3 | Recruiting | Platinum-resistant Ovarian Cancer | 82 | 2027-09 |
| EPCORE™ NHL-2 NCT04663347 |
P1/2 | Active, not recruiting | Diffuse Large B-Cell Lymphoma; Follicular Lymphoma | 543 | 2027-09-30 (+68 mo) |
| Epcoritamab NCT05201248 |
P1/2 | Active, not recruiting | B-Cell Non-Hodgkin Lymphoma | 49 | 2027-10 (+46 mo) |
| RAINFOL-05 NCT07288177 |
P2 | Recruiting | Non-small Cell Lung Cancer (NSCLC) | 240 | 2027-11-22 |
| EPCORE™ CLL-1 NCT04623541 |
P1/2 | Active, not recruiting | Relapsed/Refractory Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | 194 | 2027-12 (+60 mo) |
| Petosemtamab NCT06525220 |
P3 | Active, not recruiting | Head and Neck Squamous Cell Carcinoma | 699 | 2028-01 |
| Petosemtamab NCT06496178 |
P3 | Active, not recruiting | Head and Neck Squamous Cell Carcinoma | 621 | 2028-02 |
| EPCORE DLBCL-4 NCT06508658 |
P3 | Active, not recruiting | Diffuse Large B-Cell Lymphoma | 379 | 2028-03 (+3 mo) |
| MCLA-158 NCT03526835 |
P1/2 | Recruiting | Advanced/Metastatic Solid Tumors; Colorectal Cancer | 560 | 2028-05 (+88 mo) |
| RAINFOL-09 NCT07539311 |
P2 | Recruiting | Gastrointestinal Cancers | 160 | 2028-09 |
| RAINFOL-04 NCT07225270 |
P3 | Recruiting | Ovarian Cancer; Platinum-sensitive Ovarian Cancer | 544 | 2028-10 |
| RAINFOL-01 NCT05579366 |
P1/2 | Recruiting | High Grade Epithelial Ovarian Cancer; High Grade Serous Ovarian Cancer | 952 | 2028-12 (+47 mo) |
| EPCORE™ NHL-1 NCT03625037 |
P1/2 | Active, not recruiting | DLBCL; High-grade B-cell Lymphoma (HGBCL) | 666 | 2029-01 (+83 mo) |
| Petosemtamab NCT07775287 |
P3 | Recruiting | Colorectal Cancer | 600 | 2029-03-30 |
| Petosemtamab NCT07702032 |
P3 | Recruiting | Left-sided Colorectal Cancer | 960 | 2029-07 |
| RAINFOL-03 NCT07166094 |
P3 | Recruiting | Endometrial Cancer; Recurrent or Progressive Endometrial Cancer | 660 | 2029-08 (+9 mo) |
| RAINFOL™-07 NCT07564141 |
P3 | Recruiting | Platinum-Sensitive Ovarian Cancer; Ovarian Cancer | 688 | 2029-12 |
| EPCORE FL-1 NCT05409066 |
P3 | Active, not recruiting | Follicular Lymphoma (FL) | 549 | 2029-12 |
| RAINFOL™-10 NCT07859215 |
P3 | Not yet recruiting | Ovarian Cancer | 602 | 2030-03 |
| Epcoritamab NCT05283720 |
P2 | Active, not recruiting | Non-Hodgkin Lymphoma | 264 | 2032-11 (+41 mo) |
| EPCORE™FL-2 NCT06191744 |
P3 | Active, not recruiting | Follicular Lymphoma (FL) | 1095 | 2037-11 (+109 mo) |